Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSTA-MD in treatment-resistant major depressive disorder
2022-501692-35-00Phase 3Authorised
- Sponsor
- University of Antwerp
- Start
- Sep 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Celecoxib augmentation, Minocycline augmentation and Placebo augmentation (3 arms). Primary endpoints: Change in HDRS-17 score and Remission rate by HDRS-17. Planned start Sep 2023; status: authorised.
02
Drugs
celecoxibminocycline
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2022-501692-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501692-35-00.